The key to the mechanism of action is that after antibody binding, the cytotoxic payload can be directly delivered to tumor cells, limiting potential resistance mechanisms related to intracellular signaling, such as ME3 amplification in EGFR TKI resistance. This evidence concerns the gene EGFR and neoplasm.